// App-Quantinova.ai

: EXTH-50. THIOREDOXIN REDUCTASE1 AND MGMT SYNTHETIC LETHALITY ENHANCES CYTOTOXICITY OF PRIMA-1MET(APR-246) AND AURANOFIN IN GLIOBLASTOMA

Researchers

Presenter

  • Rehka Raveendrakumar

Principal Investigators

  • Bassam Abdulkarim

  • Monisha Bagchi

  • Paul Daniel

  • Aymane Deri

  • Bertrand Jean-Claude

  • Siham Sabri

Medical Centers

  • Montreal University, Montreal, QC, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

  • Solid malignancies

Biomarkers

  • p53

  • Proto-oncogene tyrosine-protein kinase ROS

Drug/Treatment

  • buthionine sulfoximine

  • O6-benzylguanine

  • N-acetylcysteine

  • Acetylcysteine Injection

  • Temozolomide

  • thioredoxin

  • auranofin

  • APR-246

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved